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Abstract
Background: Surgery for advanced gastric cancer (AGC) often includes dissection of splenic hilar lymph nodes
(SHLNs). This study compared the safety and effectiveness of different approaches to SHLN dissection for upper-
and/or middle-third AGC.
Methods: We retrospectively compared and analyzed clinicopathologic and follow-up data from a prospectively
collected database at the Peking University Cancer Hospital. Patients were divided into three groups: in situ spleen-
preserved, ex situ spleen-preserved and splenectomy.
Results: We analyzed 217 patients with upper- and/or middle-third AGC who underwent R0 total or proximal
gastrectomy with splenic hilar lymphadenectomy from January 2006 to December 2011, of whom 15.2 % (33/
217) had metastatic SHLNs, and from whom 11.4 % (53/466) of the dissected SHLNs were metastatic. The number
of harvested SHLNs per patient was higher in the ex situ group than in the in situ group (P = 0.017). Length of
postoperative hospital stay was longer in the splenectomy group than in the in situ group (P = 0.002) or the ex
situ group (P < 0.001). The splenectomy group also lost more blood volume (P = 0.007) and had a higher postoperative
complication rate (P = 0.005) than the ex situ group. Kaplan–Meier (log rank test) analysis showed significant survival
differences among the three groups (P = 0.018). Multivariate analysis showed operation duration (P = 0.043), blood loss
volume (P = 0.046), neoadjuvant chemotherapy (P = 0.005), and N stage (P < 0.001) were independent prognostic
factors for survival.
Conclusions: The ex situ procedure was more effective for SHLN dissection than the in situ procedure without
sacrificing safety, whereas splenectomy was not more effective, and was less safe. The SHLN dissection method was
not an independent risk factor for survival in this study.
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Background
The estimated incidence and mortality of gastric cancer
in 2013 were 984,000 and 841,000 worldwide, respect-
ively [1, 2]. Globally, gastric cancer is the fifth most
common cancer and the second most common cause of
cancer death. More than 70 % of these cases occur in
developing countries, with half arising in Eastern Asia
(mainly Korea, Japan, and China). Surgery is the primary
treatment for gastric cancer, with D2 lymphadenectomy
widely accepted for advanced gastric cancer (AGC) in
both Eastern and Western countries [3–5].
The incidence of upper- and/or middle-third gastric
cancer has steadily increased, especially in Asia [6].
According to the 2010 Japanese gastric cancer treatment
guideline (ver. 3) published by the Japanese Gastric
Cancer Association, the extent of systematic lymphade-
nectomy depends on the type of gastrectomy [7]. The
lymph node stations surrounding the stomach have
been precisely defined by the Japanese Gastric Cancer
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Association (Table 1 and Fig. 1). To achieve sufficient
negative proximal margins, most patients with upper-
and/or middle-third AGC require total gastrectomies
with D2 lymphadenectomies that include the splenic
hilar lymph nodes (SHLNs; No. 10 lymph nodes) [8].
Reportedly, 7.3–26 % of SHLNs in upper- and/or
middle-third AGC are metastatic [9–12]. Prophylactic
splenectomy, in situ and ex situ spleen-preserving lym-
phadenectomies have been the most common dissection
approaches for SHLNs. Prophylactic splenectomy was a
common procedure for D2 dissection until the results of
the Japanese Clinical Oncology Group (JCOG) 0110
study that showed a non-inferiority of spleen preserva-
tion compared with splenectomy in terms of overall
survival [13, 14]. Nonetheless, as the JCOG 0110 study
included only tumors from the lesser curvature, the
approach for patients with tumors at the greater curva-
ture is still in doubt.
Two main operative procedures for SHLN dissection
spare the spleen. Ex situ and in situ dissection are
defined depending on whether the pancreas and spleen
are treated within the peritoneal cavity or not. The in
situ dissection approach is more difficult as the SHLN
dissection is implemented in a narrow and small space,
and can thus lead to bleeding; however, it avoids moving
the pancreas and spleen and shortens surgical time. In
contrast, ex situ dissection is performed under direct
vision, which provides a better exposure, and is thus less
difficult.
To our knowledge, no previous study has directly
compared the effectiveness and safety of these three
approaches. We therefore investigated which of these
three dissection approaches was better for patients with
upper- and/or middle-third AGC.
Methods
Patients
This study was performed after approval by the Ethics
Committee of Peking University Cancer Hospital.
Informed consent was obtained from each patient. We
retrospectively collected clinical and pathological data
from a prospectively collected database at the Peking
University Cancer Hospital. We included 217 patients
with upper- and/or middle-third AGC who had under-
gone R0 total or proximal gastrectomy with SHLN
dissection from January 2006 to December 2011. Their
primary diagnoses were confirmed by endoscopic biop-
sies analysis. Clinical staging was mainly confirmed by
ultrasound endoscopy, chest, abdominal and pelvic com-
puted tomography scans, and laparoscopic exploration.
Patients with other types of tumors, such as gastrointes-
tinal stromal tumor or lymphoma, were excluded.
Surgical procedure
All the enrolled patients underwent laparoscopic explor-
ation to exclude distant metastatic disease. After that, all
the patients received R0 resection with total or proximal
Table 1 Regional lymph nodes for gastric cancer
No Definition
1 Right paracardial LNs
2 Left paracardial LNs
3a Lesser curvature LNs along the branches of the left gastric artery
3b Lesser curvature LNs along the 2nd branch and distal part of the
right gastric artery
4sa Left greater curvature LNs along the short gastric arteries
4sb Left greater curvature LNs along the left gastroepiploic artery
4d Left greater curvature LNs along the 2nd branch and distal part
of the right gastroepiploic artery
5 Suprapyloric LNs along the 1st branch and proximal part of the
right artery
6 Infrapyloric LNs along the 1st branch and proximal part of the
right gastroepiploic artery
7 LNs along the trunk of left gastric artery between its root and
the origin of tis ascending branch
8a Anterosuperior LNs along the common hepatic artery
8p Posterior LNs along the common hepatic artery
9 Celiac artery LNs
10 Splenic hilar LNs
11p Proximal splenic artery LNs
11d Distal splenic artery LNs
12a Hepatoduodenal ligaments LNs along the proper hepatic artery
12p Hepatoduodenal ligaments LNs along the portal vein
12b Hepatoduodenal ligaments LNs along the bile duct
LNs lymph node
Fig. 1 Definition of lymph node stations of gastric cancer. The
lymph nodes of stomach are defined and given station numbers.
Lymph node stations1-7, 8a, 9, 10, 11p, 11d and 12a are included in
the D2 dissection for locally advanced upper and/or middle third
gastric cancer
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gastrectomy and SHLN dissection. The lymph node
dissection scope was mainly D2/D2+, according to the
definition in the Japanese gastric cancer treatment
guidelines [7]. The approach of SHLN dissection was at
the discretion of the surgeon during the operation.
In the splenectomy group, splenectomy was performed
with full mobilization of the distal pancreas and spleen.
Lymph nodes along the splenic artery were completely
dissected. The splenic artery was usually ligated and di-
vided 5–6 cm away from its origin. The spleen and
lymph nodes at the hilum of the spleen were removed,
with the pancreas preserved.
In the in situ spleen-preserved group, the spleen and
the pancreas were not mobilized from the retroperito-
neum. Lymph nodes along the splenic artery were
dissected. All the soft tissues at the splenic hilum were
removed as cautiously as possible.
In the ex situ spleen-preserved group, splenic hilar
lymphadenectomy was performed with full mobilization
of the distal pancreas and spleen. The spleen was moved
outside the peritoneal cavity. Lymph nodes along the
splenic artery and at the splenic hilum were completely
dissected, with the pancreas and spleen preserved, and
then replaced into the peritoneal cavity.
After the surgery, the patients stayed in hospital to get
recovery. Before they left the hospital, the discharge
criteria must be all fulfilled. The discharge criteria
included: absence of subjective complaints, tolerance of
solid oral intake, return of bowel function, absence of
intravenous fluids/medications, adequate mobility of
daily living and self-care (eg, go to toilet, dress, shower,
etc.), adequate pain control on oral analgesia only,
adequate wound condition, removal of drainage tube,
absence of infectious complications, absence of postop-
erative complications, absence of abnormal physical
signs or laboratory test (eg, pulse, body temperature,
white blood cell count, serum hemoglobin, etc.), accept-
ance of discharge, adequate home/social condition.
Clinicopathologic parameters
The clinicopathological data collected from the database
included age, sex, body mass index (BMI), neoadjuvant
chemotherapy (NACT) regimens, tumor location, tumor
size, presence of multi-tumor, range of gastrectomy,
degree of lymph node dissection (LND), SHLN dissec-
tion procedure, tumor differentiation, lymphovascular
invasion (LVI), depth of tumor invasion, number of har-
vested and metastatic lymph nodes, postoperative com-
plications, mortality, length of postoperative hospital
stay, operation duration, blood loss volume, and sur-
vival outcomes. Terminology used to describe the clini-
copathologic parameters was based on the Japanese
Gastric Cancer Association classification of gastric
carcinoma [8].
Follow-up
Follow-up was conducted mainly through telephone in-
terviews, E-mail communication, or outpatient reviews.
As of April 26, 2016, the percentage of follow-up was
96.7 % (210/217).
Statistical analysis
All statistical analysis was performed through IBM SPSS
Statistics 20.0 software (SPSS Inc., Armonk, NY). For
quantitative variables, normal distribution was tested
first. Variables of normal distribution were expressed as
means ± standard deviation, and tested by analysis of
variance among the three groups. If not, the variables
were expressed as medians with ranges, and compared
by Kruskal–Wallis non-parametric test. For categorical
data, the chi-squared test or Fisher’s exact test was per-
formed. Kaplan–Meier estimation and the log-rank tests
were used to calculate survival. In the pairwise compari-
sons, the original calculated P value and the Bonferroni-
corrected threshold were listed. If the P value was less
than this Bonferroni-corrected threshold, then the com-
parison was considered to be statistically significant. Cox
proportional hazards regression model was used to
confirm independent prognostic factors through univari-
ate and multivariate analysis. Except in the pairwise
comparison, P < 0.05 (two-sided) was considered signifi-
cant in the statistical analysis.
Results
Clinicopathologic parameters
We analyzed 217 patients in this retrospective study,
who were divided into three groups: in situ (n = 68), ex
situ (n = 118), and splenectomy (n = 31). Some of the
patients in the splenectomy group had intended to
undergo in situ or ex situ approach after abdominal ex-
ploration, but encountered unintended splenic injury
resulting in splenectomy. Of all the thirty-one patients
in the splenectomy group, two patients underwent conver-
sion from in situ approach to splenectomy, and three pa-
tients underwent conversion from ex situ approach to
splenectomy. The rates of conversion from in situ and ex
situ procedures to splenectomy were 2.86 % (2/70) and
2.48 % (3/121), respectively. All of their clinicopathologic
factors except the number of patients who received NACT
and the range of gastrectomy were comparable among the
three groups; however, lower percentages of the in situ
group underwent NACT and total gastrectomies than the
ex situ and splenectomy groups (Table 2).
Splenic hilar lymphadenectomy
All 217 patients in our study underwent SHLN dissec-
tion, and all of the dissected lymph nodes were con-
firmed by pathological examination. Of the 217 patients,
33 (15.2 %) were found to have metastatic SHLNs,
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including 8.8 % (6/68) of the in situ group, 14.4 % (17/
118) of the ex situ group, and 32.3 % (10/31) of the
splenectomy group (P = 0.010). Of 466 harvested
SHLNs, 11.4 % (53/466) were metastatic, including
8.3 % (10/121) in the in situ group, 11.8 % (32/271) in
the ex situ group, and 14.9 % (11/74) in the splenec-
tomy group (P = 0.349).
Intraoperative and postoperative parameters
Surgery-related parameters were compared among the
three groups (Tables 3 and 4), and were found to differ
significantly in the number of harvested SHLNs per
patient (P = 0.047), length of postoperative hospital stay
(P = 0.001), and blood loss volume (P = 0.027). Further
paired comparisons revealed that the number of
harvested SHLNs per patient was higher in the ex situ
group than in the in situ group (P = 0.015). The length
of postoperative hospital stay was significantly longer in
the splenectomy group than in the other two groups
(splenectomy vs in situ: P = 0.002; splenectomy vs ex
situ: P < 0.001). The splenectomy group also had signifi-
cantly greater blood loss volume than did the ex situ
group (P = 0.007). The three groups did not signifi-
cantly differ in total harvested lymph nodes per
patient (P = 0.313) or operation duration (P = 0.695).
Postoperative complication rates were: in situ group:
17.6 % (12/68); ex situ group: 12.7 % (15/118); and
splenectomy group: 35.5 % (11/31; P = 0.011); and were
notably higher in the splenectomy group than in the ex
situ group (P = 0.005; paired comparison). The three
groups did not significantly differ in reoperation rate
(P = 0.359) or postoperative mortality rate (P = 0.363).
Survival outcomes
As of April 26, 2016, median follow-up time was
33.2 months (range: 1–111 months). Median survival
Table 2 Patients’ clinicopathologic parameters
In situ
(n = 68), n(%)
Ex situ





Male 47(69.1) 91(77.1) 26(83.9)
Female 21(30.9) 27(22.9) 5(16.1)
Age 1.000
< 60 36(52.9) 63(53.4) 17(54.8)
≥ 60 32(47.1) 55(46.6) 14(45.2)
BMI 0.716
< 19 5(7.4) 10(8.5) 1(3.2)
~ <25 46(67.6) 83(70.3) 22(71.0)
~ <30 17(25) 22(18.6) 7(22.6)
≥ 30 0(0) 3(2.5) 1(3.2)
NACT 0.008
No 42(61.8) 48(40.7) 11(35.5)
Yes 26(38.2) 70(59.3) 20(64.5)
Degree of LND 0.090
D1+ 5(7.4) 7(5.9) 1(3.2)
D2 58(85.3) 84(71.2) 23(74.2)
D2+ 5(7.4) 27(22.9) 7(22.6)
Gastrectomy 0.033
Proximal 28(41.2) 34(28.8) 5(16.1)
Total 40(58.8) 84(71.2) 26(83.9)
Differentiation 0.115
Well 1(1.5) 9(7.6) 5(16.1)
Moderate 31(45.6) 53(44.1) 12(38.7)
Poor 36(52.9) 57(48.3) 14(45.2)
LVI 0.060
No 26(38.8) 66(55.9) 12(41.4)
Yes 41(61.2) 52(44.1) 17(58.6)
Location 0.648
EGJ 35(51.5) 63(53.4) 12(38.7)
U/UM 7(10.3) 10(8.5) 6(19.4)
M/MU 24(35.3) 43(36.4) 12(38.7)
EUM 2(2.9) 2(1.7) 1(3.2)
Tumor size 0.548
≤ 2 cm 7(10.3) 10(8.5) 2(6.5)
~≤5 cm 35(51.5) 56(47.5) 10(32.2)
~≤10 cm 21(30.9) 40(33.9) 14(45.2)
> 10 cm 5(7.4) 12(10.2) 5(16.1)
Multi-tumor 0.095
No 68(100) 115(97.5) 29(93.5)
Yes 0 3(2.5) 2(6.5)
Table 2 Patients’ clinicopathologic parameters (Continued)
T stagea 0.059
T2 5(7.4) 11(9.3) 2(6.5)
T3 5(7.4) 1(0.8) 1(3.2)
T4a 51(75.0) 101(85.6) 23(74.2)
T4b 7(10.3) 5(4.2) 5(16.1)
N stagea 0.230
N0 8(11.8) 35(29.7) 5(16.1)
N1 13(19.1) 16(13.6) 7(22.6)
N2 16(23.5) 26(22.0) 6(19.4)
N3a 18(26.5) 21(17.8) 8(25.8)
N3b 13(19.1) 20(16.9) 5(16.1)
BMI body mass index, NACT neoadjuvant chemotherapy, LND lymph node
dissection, LVI lymphovascular invasion, EGJ esophagogastric junction, E
esophagus, U upper, M middle
a7th UICC/AJCC TNM classification for gastric cancer
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times were: in situ group: 34.5 months, ex situ group:
71.1 months, and splenectomy group: 21.1 months; 5-
year overall survival rates were: in situ group: 46 %, ex
situ group: 50 %, and splenectomy group: 23 %. The three
groups were found to significantly differ by Kaplan–Meier
survival analysis (log rank test; P = 0.018; Fig. 2), especially
the splenectomy and ex situ groups (P = 0.005; paired
comparisons; Fig. 2).
Risk factors found in the univariate analysis included
SHLN dissection method, operation duration, blood loss vol-
ume, postoperative complications, use of NACT, presence of
multiple tumors, differentiation, tumor size, T stage, N stage,
LVI, and range of gastrectomy (Table 5). All these factors
were subjected to multivariate analysis, which found oper-
ation duration (P= 0.043), blood loss volume (P= 0.046), use
of NACT (P= 0.005), and N stage (P < 0.001) to be inde-
pendent prognostic factors for survival (Table 5).
Discussion
Although the incidence of gastric cancer has decreased
worldwide, upper- and/or middle-third AGC has shown
an increasing trend. As far as we know, the only way to
cure gastric cancer is radical surgery, which includes
gastrectomy and lymph node dissection. The currently
recommended surgical procedure for advanced upper-
and/or middle-third gastric cancer is total gastrectomy
with D2 lymph node dissection [7]. SHLNs are defined
as group No.10 lymph nodes, which are included in D2
dissection. Reportedly, the incidence of SHLN metastasis
in the upper- and/or middle-third AGC is 7.3–26 %,
which was higher than in the lower-third gastric cancers
[9–12, 15–17]. In our study, the incidence of metastasis
of SHLNs was 15.2 % (33/217), which was similar to pre-
vious reported studies, while the rates in the in situ, ex
situ, and splenectomy groups were 8.8 % (6/68), 14.4 %
(17/118), and 32.3 % (10/31), respectively (P = 0.010).
Surgeons were inclined to use ex situ or splenectomy
procedures for SHLNs suspected of having metastases,
to perform dissections more effectively.
Optimal procedure for SHLN dissection has long been
debated. Many previous studies have reported that
splenectomy in this situation did not lead to longer
survival [12, 18, 19], and in fact might increase surgical
complication and mortality rate. During splenectomy,
the pancreas tail and spleen are mobilized, which often
leads to pancreatic fistulae or abscess formation. More-
over, loss of the spleen and its effect on immune func-
tion might adversely affect the recovery process. In 2016,
the JCOG 0110 study reported that prophylactic splen-
ectomy should be avoided for both surgical safety and
survival benefit in total gastrectomies for proximal
Table 3 Patients’ intraoperative and postoperative parameters
In situ (n = 68) Ex situ (n = 118) Splenectomy (n = 31) Pvalue
No. of harvested SHLNs, median (range) 1(1–4) 2(1–7) 2(1–7) 0.047
No. of total harvested LNs, median (range) 33(10–66) 33(11–78) 31(11–60) 0.313
Postoperative hospital stay, days, (mean ± standard deviation) 16.41 ± 3.06 15.11 ± 1.53 23.26 ± 4.74 0.001
Blood loss volume, ml, (mean ± standard deviation) 211.62 ± 53.43 180.08 ± 24.71 262.90 ± 78.09 0.027
Operation duration, min, (mean ± standard deviation) 242.66 ± 18.90 244.24 ± 13.66 247.65 ± 22.06 0.695
Postoperative complication rate, n (%) 12(17.6 %) 15(12.7 %) 11(35.5 %) 0.011
Bleeding, n (%) 1 (1.5 %) 3 (2.5 %) 3 (9.7 %) 0.153
Anastomotic leak, n (%) 3 (4.4 %) 6 (5.1 %) 5 (16.1 %) 0.111
Pancreatic fistula, n (%) 0 (0.0 %) 0 (0.0 %) 2 (6.5 %) 0.019
Abdominal effusion, n (%) 6 (8.8 %) 7 (5.9 %) 5 (16.1 %) 0.183
Abdominal infection, n (%) 6 (8.8 %) 8 (6.8 %) 7(22.6 %) 0.029
Pneumonia, n (%) 3 (8.8 %) 1 (0.8 %) 1(3.2 %) 0.269
Reoperation rate, n (%) 3(4.4 %) 3(2.5 %) 2(6.5 %) 0.359
Mortality rate, n (%) 0(0 %) 1(0.8 %) 1(3.2 %) 0.363
SHLNs splenic hilar lymph nodes, LNs lymph nodes









No. of harvested SHLNs 0.154 0.015 0.755
Postoperative hospital stay 0.002 0.832 <0.001




SHLNs splenic hilar lymph nodes, LNs lymph nodes
*Bonferroni correction was carried out. P < 0.017 (two-sided) was
considered significant
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gastric cancers that do not invade the greater curvature
[14]. Although patients whose cancers involved the
greater curvature were not included in the JCOG 0110
study, it was the largest randomized clinical trial of
splenectomy in gastric cancer, and demonstrated signifi-
cant non-inferiority of spleen preservation for the first
time. In our study, splenectomy reduced surgical
safety and slowed the speed of postoperative recovery
in terms of operative blood loss volume and postoper-
ative hospital stay, compared with the spleen-sparing
procedures. Our splenectomy group had longer aver-
age postoperative hospital stay, higher average blood
loss volume, and a higher postoperative complication
rate than the ex situ group, which was in accordance
with earlier studies [19–21].
We found ex situ procedure was more effective for SHLN
dissection than in situ splenic-preserving procedure and
did not sacrifice surgical safety. Ex situ spleen-preserving
procedure might improve the integrity of lymphadenec-
tomy at the splenic hilum [22]. In the ex situ group, dissec-
tion of SHLNs was conducted under direct vision, and
allowed surgeons to protect blood vessels and clear fatty
tissues at the splenic hilum much more easily than in the in
situ group, where dissection of SHLNs was very difficult
and injury to spleen and blood vessels sometimes occurred.
Therefore, although more time was required to mobilize
the spleen and pancreas tail, the time needed to dissect
SHLNs was significantly reduced. For this reason, operation
duration was comparable between the in situ and ex situ
groups. In our study, the ex situ procedure was more effect-
ive, and did not increase operation duration.
Interestingly, although Kaplan–Meier and log-rank analysis
showed significant differences in survival among the three
groups, Cox regression analysis of proportional hazards did
not show SHLN dissection procedure to be an independent
risk factor for survival. The significant difference shown in
the Kaplan–Meier method might be caused by some other
factors such as the imbalance of grouping in our study. The
higher postoperative complication rate in the splenectomy
group probably had adverse effects on survival, which is sup-
ported by earlier studies [23, 24].
Our study also had some limitations. First, it was a retro-
spective study, and selection bias was difficult to avoid. For
instance, the percentages of patients who received NACT
were much higher in the splenectomy and ex situ groups,
probably because patients with later-stage disease were
more likely to receive NACT. The choice of lymphadenec-
tomy procedure was decided by surgeons, who usually
chose patients with later-stage disease for ex situ or splen-
ectomy procedures, as these methods seem to be more
effective means to dissect the SHLNs. Similarly, more
patients in the splenectomy or ex situ groups underwent
Fig. 2 Survival curves for three groups. The ex vivo, in vivo, and splenectomy groups significantly differed in survival (P = 0.018, log-rank test). This
difference was especially pronounced between the ex situ and splenectomy groups (P = 0.005, P < 0.017). In the pairwise comparisons, Bonferroni
modification was carried out. P < 0.017 (two-sided) was considered significant
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total gastrectomies, which are more suitable for patients
with later-stage disease. The three groups did not signifi-
cantly differ with regard to other clinicopathologic param-
eters. Second, as the sample size in the splenectomy group
was much smaller than that in the other two groups, a
type II error might have occurred.
Conclusions
Ex situ SHLN dissections were safer than splenectomies.
Compared with in situ procedures, ex situ procedures
apparently dissected SHLNs more effectively. Although
the survival in these three groups significantly differed in
Kaplan–Meier analysis, SHLN dissection method was not
an independent risk factor for survival. Multicenter, large-
scaled, randomized controlled trials are needed to clarify
the optimal splenic hilar lymphadenectomy procedure.
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Blood loss
volume
















Moderate 1.200(0.512,2.816) 0.674 1.155(0.474,2.818) 0.751
Poor 1.886(0.816,4.361) 0.138 1.550(0.643,3.734) 0.329
Tumor size 0.007 0.135
≤ 2 cm 1 1
~≤5 cm 3.075(1.110,8.524) 0.031 2.931(0.877,9.794) 0.081
~≤10 cm 4.227(1.520,11.754) 0.006 3.420(0.989,11.828) 0.052
> 10 cm 5.702(1.888,17.220) 0.002 4.710(1.254,17.684) 0.022




T4a 1.728(0.872,3.428) 0.117 1.541(0.651,3.652) 0.326
T4b 3.036(1.275,7.227) 0.012 1.645(0.604,4.482) 0.330
N stagea <0.001 <0.001
N0 1 1
N1 1.482(0.755,2.908) 0.253 1.398(0.696,2.808) 0.347
N2 1.937(1.308,3.616) 0.038 1.836(0.933,3.609) 0.078
N3a 1.714(0.904,3.250) 0.099 1.958(0.988,3.883) 0.054







BMI body mass index, EGJ esophagogastric junction, E esophagus, U upper, M
middle, LND lymph node dissection, SHLN splenic hilar lymph node, NACT
neoadjuvant chemotherapy, LVI lymphovascular invasion
a7th UICC/AJCC TNM classification for gastric cancer
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